Nevro (NYSE:NVRO) Issues Earnings Results, Beats Estimates By $0.15 EPS

Nevro (NYSE:NVRO) announced its quarterly earnings results on Tuesday. The medical equipment provider reported ($0.64) EPS for the quarter, beating the consensus estimate of ($0.79) by $0.15, Zacks reports. Nevro had a negative net margin of 16.54% and a negative return on equity of 23.52%.

Nevro Stock Performance

NYSE:NVRO traded up $0.02 during mid-day trading on Tuesday, reaching $5.74. The stock had a trading volume of 627,761 shares, compared to its average volume of 657,294. The firm has a market capitalization of $214.90 million, a price-to-earnings ratio of -3.03 and a beta of 0.94. The business has a 50 day simple moving average of $4.82 and a 200 day simple moving average of $4.93. Nevro has a twelve month low of $3.17 and a twelve month high of $15.98. The company has a debt-to-equity ratio of 0.67, a quick ratio of 3.76 and a current ratio of 5.02.

Analysts Set New Price Targets

NVRO has been the topic of several research analyst reports. Jefferies Financial Group upgraded shares of Nevro from an “underperform” rating to a “hold” rating and lifted their price target for the stock from $4.50 to $5.85 in a research note on Monday, February 10th. Royal Bank of Canada reissued a “sector perform” rating and issued a $7.00 target price on shares of Nevro in a research report on Tuesday, November 12th. Piper Sandler upgraded Nevro from a “neutral” rating to an “overweight” rating and dropped their price target for the stock from $6.00 to $5.85 in a research note on Friday, February 7th. Truist Financial reduced their price objective on Nevro from $7.00 to $4.70 and set a “hold” rating for the company in a research note on Wednesday, December 18th. Finally, Wells Fargo & Company lowered their target price on shares of Nevro from $5.00 to $4.00 and set an “equal weight” rating on the stock in a research report on Wednesday, December 11th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $6.43.

Nevro Company Profile

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.